At TAE Life Sciences, our mission is to advance Boron Neutron Capture Therapy (BNCT). Our foundational accelerator beam technology is derived from decades of development by TAE Technologies, Inc., an innovative leader in fusion energy technology. Leveraging their groundbreaking work for clinical investigation, TAE Life Sciences is developing the next generation of low-energy neutron beams - optimized for BNCT and practical for typical hospital settings. We have assembled a world-class, cross-functional team of clinicians, radiation oncologists, physicists and other researchers to enable us to bring our technology to those who need it most.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/13/18 | $40,000,000 | Series A |
Artis Ventures | undisclosed |
| 06/04/20 | $30,000,000 | Series B |
Artis Ventures | undisclosed |
